Arkolith/Insider Trading/AKTS/Form 4

Foley Todd

Director, 10% OwnerAktis Oncology, Inc. (AKTS) · full profile →Form 4 · filed Jan 14, 2026
Net Buying
Open-Market Buys
$4.2M
Open-Market Sells
$0
Net Open-Market Flow
$4.2M
Transactions
7
4 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 12, 2026Conversion(C)2.7M——3.3M
Jan 12, 2026Buy(P)233K$18.00$4.2M4.2M
Jan 12, 2026Conversion(C)597K——597K
Jan 12, 2026Conversion(C)717K——4.0M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 12, 2026Conversion(C)2.3M—$00
Jan 12, 2026Conversion(C)2.7M—$00
Jan 12, 2026Conversion(C)10.2M—$00

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001473930-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML